TY - JOUR
T1 - Predictors of Major Atrial Fibrillation Endpoints in the National Heart, Lung, and Blood Institute HCMR
AU - HCMR Investigators
AU - Kramer, Christopher M.
AU - DiMarco, John P.
AU - Kolm, Paul
AU - Ho, Carolyn Y.
AU - Desai, Milind Y.
AU - Kwong, Raymond Y.
AU - Dolman, Sarahfaye F.
AU - Desvigne-Nickens, Patrice
AU - Geller, Nancy
AU - Kim, Dong Yun
AU - Maron, Martin S.
AU - Appelbaum, Evan
AU - Jerosch-Herold, Michael
AU - Friedrich, Matthias G.
AU - Schulz-Menger, Jeanette
AU - Piechnik, Stefan K.
AU - Mahmod, Masliza
AU - Jacoby, Daniel
AU - White, James
AU - Chiribiri, Amedeo
AU - Helms, Adam
AU - Choudhury, Lubna
AU - Michels, Michelle
AU - Bradlow, William
AU - Salerno, Michael
AU - Dawson, Dana K.
AU - Weinsaft, Jonathan W.
AU - Berry, Colin
AU - Nagueh, Sherif F.
AU - Buccarelli-Ducci, Chiara
AU - Owens, Anjali
AU - Casadei, Barbara
AU - Watkins, Hugh
AU - Weintraub, William S.
AU - Neubauer, Stefan
N1 - Funding Information:
This work was supported by the National Institutes of Health, the National Heart, Lung, and Blood Institute (U01HL117006-01A1) and the Oxford NIHR Biomedical Research Centre. Dr. Kramer has received research grants from MyoKardia and Cytokinetics; and has been consultant for MyoKardia and Cytokinetics. Dr. DiMarco has been a consultant to Novartis, Galmed, and Celgene. Dr. Ho has been consultant for and has received research support from MyoKardia. Dr. Kwong has received research support from Siemens Healthineers, Bayer AG, and Myokardia. Dr. Maron has received consulting and research support from iRhythm; and has been a consultant for Celltrion and Cytokinetics. Dr. Friedrich has been a board member, shareholder, and consultant of Circle Cardiovascular Imaging Inc. Dr. Schulz-Menger has been a consultant for Bayer; has received research grants from Bayer, Siemens Healthineers, and Circle Cardiovascular Imaging. Dr. Piechnik holds U.S. patent 9,285,446 B2: “Systems and methods for shortened look locker inversion recovery (Sh-MOLLI) cardiac gated mapping of T1.” Dr. Jacoby has been consultant for and has received a research grant from MyoKardia. Dr. White holds shares in Cohesic; and has received a research grant from Siemens Healthineers. Dr. Chiribiri has received research grants from Philips Healthcare and Siemens Healthineers. Dr. Helms has received research support from MyoKardia. Dr. Bradlow has received honoraria from Daichi-Sankyo. Dr. Salerno has received research support from Siemens Healthineers and Heartflow. Dr. Dawson has received research grant from Philips Healthcare. Dr. Nagueh has been a consultant for MyoKardia. Dr. Casadei has received research support from Roche Diagnostics and iRhythm. Dr. Watkins has been a consultant for Cytokinetics. Dr. Neubauer has received research grants from Boehringer Ingelheim and Cytokinetics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2021 American College of Cardiology Foundation
PY - 2021/11
Y1 - 2021/11
N2 - Objectives: This study sought to identify predictors of major clinically important atrial fibrillation endpoints in hypertrophic cardiomyopathy. Background: Atrial fibrillation (AF) is a common morbidity associated with hypertrophic cardiomyopathy (HCM). The HCMR (Hypertrophic Cardiomyopathy Registry) trial is a prospective natural history study of 2,755 patients with HCM with comprehensive phenotyping. Methods: All patients received yearly telephone follow-up. Major AF endpoints were defined as requiring electrical cardioversion, catheter ablation, hospitalization for >24 h, or clinical decisions to accept permanent AF. Penalized regression via elastic-net methodology identified the most important predictors of major AF endpoints from 46 variables. This was applied to 10 datasets, and the variables were ranked. Predictors that appeared in all 10 sets were then used in a Cox model for competing risks and analyzed as time to first event. Results: Data from 2,631 (95.5%) patients were available for analysis after exclusions. A total of 127 major AF endpoints events occurred in 96 patients over 33.3 ± 12.4 months. In the final model, age, body mass index (BMI), left atrial (LA) volume index, LA contractile percent (active contraction), moderate or severe mitral regurgitation (MR), and history of arrhythmia the most important. BMI, LA volume index, and LA contractile percent were age-dependent. Obesity was a stronger risk factor in younger patients. Increased LA volume, reduced LA contractile percent, and moderate or severe MR put middle-aged and older adult patients at increased risk. Conclusions: The major predictors of major AF endpoints in HCM include older age, high BMI, moderate or severe MR, history of arrhythmia, increased LA volume, and reduced LA contractile percent. Prospective testing of a risk score based on these parameters may be warranted.
AB - Objectives: This study sought to identify predictors of major clinically important atrial fibrillation endpoints in hypertrophic cardiomyopathy. Background: Atrial fibrillation (AF) is a common morbidity associated with hypertrophic cardiomyopathy (HCM). The HCMR (Hypertrophic Cardiomyopathy Registry) trial is a prospective natural history study of 2,755 patients with HCM with comprehensive phenotyping. Methods: All patients received yearly telephone follow-up. Major AF endpoints were defined as requiring electrical cardioversion, catheter ablation, hospitalization for >24 h, or clinical decisions to accept permanent AF. Penalized regression via elastic-net methodology identified the most important predictors of major AF endpoints from 46 variables. This was applied to 10 datasets, and the variables were ranked. Predictors that appeared in all 10 sets were then used in a Cox model for competing risks and analyzed as time to first event. Results: Data from 2,631 (95.5%) patients were available for analysis after exclusions. A total of 127 major AF endpoints events occurred in 96 patients over 33.3 ± 12.4 months. In the final model, age, body mass index (BMI), left atrial (LA) volume index, LA contractile percent (active contraction), moderate or severe mitral regurgitation (MR), and history of arrhythmia the most important. BMI, LA volume index, and LA contractile percent were age-dependent. Obesity was a stronger risk factor in younger patients. Increased LA volume, reduced LA contractile percent, and moderate or severe MR put middle-aged and older adult patients at increased risk. Conclusions: The major predictors of major AF endpoints in HCM include older age, high BMI, moderate or severe MR, history of arrhythmia, increased LA volume, and reduced LA contractile percent. Prospective testing of a risk score based on these parameters may be warranted.
KW - MRI
KW - atrial fibrillation
KW - hypertrophic cardiomyopathy
KW - left atrium
UR - http://www.scopus.com/inward/record.url?scp=85118870038&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118870038&partnerID=8YFLogxK
U2 - 10.1016/j.jacep.2021.04.004
DO - 10.1016/j.jacep.2021.04.004
M3 - Article
C2 - 34217663
AN - SCOPUS:85118870038
SN - 2405-5018
VL - 7
SP - 1376
EP - 1386
JO - JACC: Clinical Electrophysiology
JF - JACC: Clinical Electrophysiology
IS - 11
ER -